Aspira: Jumps on agreement to develop ovarian cancer test, Q4 results

Aspira Women's Health

26/03/2021 15:14

** Shares of diagnostic test maker Aspira Women's Health Inc
 AWH.O  rise 4.2% to $6.99
    ** Co on Thursday after market entered agreement with
Dana-Farber Cancer Institute, Brigham and Women's Hospital, and
Medical University Lodz to develop an early detection test for
ovarian cancer  urn:newsml:reuters.com:*:nGNX5LRSYd
    ** Ovarian cancer accounts for more deaths than any other
cancer of the female reproductive system - co
    ** Separately, co said Q4 rev rose about 7.7% to $1.4 mln,
driven by an increase in its OVA1Plus ovarian cancer detection
test volume  urn:newsml:reuters.com:*:nGNX4md7vh
    ** Stock had gained about 59.8% YTD, as of its last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))